[CAS NO. 2451-62-9] Triglycidyl isocyanurate
PRODUCTS SPECIFICATIONS [2451-62-9]
DESCRIPTION [2451-62-9]
Overview
| MDL | MFCD00080670 |
|---|---|
| Molecular Weight | 297.26 |
| Molecular Formula | C12H15N3O6 |
| SMILES | O=C(N(C1=O)CC2CO2)N(C(N1CC3CO3)=O)CC4CO4 |
Summary
Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation. Triglycidyl isocyanurate induces cell apoptosis . Triglycidyl isocyanurate can be used for cancer research [1] [2] .
In Vitro
Triglycidyl isocyanurate (0-30 μM; 48 hours) reduces the growth of spheroids of human non-small-cell-lung cancer cells in culture, it leads to a gradual reduction in size for tumorspheres of A549, H460 and H1299 cells
[1]
.
Triglycidyl isocyanurate (0-30 μM; 48 hours) inhibits expression of akt1/2/3 and phosphorylated Akt
ser
473/474/472 of A549, H460 and H1299 tumorspheres, however, the cleavage of PARP and procaspase-3 plus the emergent active caspase-3 fragment are only visible in H460 and A549 tumorspheres
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | A549, H460 and H1299 cells |
| Concentration: | 0 μM; 5 μM; 10 μM; 30 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited tumor cells growth in soft agar. |
Western Blot Analysis [1]
| Cell Line: | A549, H460 and H1299 cells |
| Concentration: | 0 μM; 5 μM; 10 μM; 30 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited akt1/2/3 expression and p-akt ser 473/474/472 expression of A549, H460 and H1299 tumorspheres |
In Vivo
Triglycidyl isocyanurate (subcutaneous injection; 1.8 and 3.6 mg/kg; every 2–3 days for total seven times; 30 days) suppresses the growth of xenograft tumors and has no effects on weight in nude mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female nu/nu mice with Huh7 cells subcutaneously injected into the dorsal area [2] |
| Dosage: | 1.8 mg/kg and 3.6 mg/kg |
| Administration: | Subcutaneous injection; every 2–3 days for total seven times; 30 days |
| Result: | Inhibited the growth of xenograft tumors. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 168.20 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3641 mL | 16.8203 mL | 33.6406 mL |
| 5 mM | 0.6728 mL | 3.3641 mL | 6.7281 mL |
| 10 mM | 0.3364 mL | 1.6820 mL | 3.3641 mL |
References
Synonyms